CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.23B, above the global median of $1.15B
- FinancialsAltman Z-Score 10.02: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
117.34BINR1.23B · vs all stocks (USD)
Trailing P/E
123.42xRevenue (TTM)
16.58BINR174.13M · vs all stocks (USD)
Profit Margin
2.52%Beta
0.9640xvs all stocks
52-Week Change
43.13%vs all stocks
Market Capitalization
117.34BINR1.23B · vs all stocks (USD)
Enterprise Value
55.23BINR580.05M · vs all stocks (USD)
Trailing P/E
123.42xForward P/E
39.84xPEG Ratio
0.2304xPrice to Sales (TTM)
5.29xPrice to Book (MRQ)
6.21xEnterprise to Revenue
3.33xEnterprise to EBITDA
30.04xGross Margin
54.46%Profit Margin
2.52%Operating Margin
9.66%Return on Assets (TTM)
4.91%Return on Equity (TTM)
6.64%Revenue (TTM)
16.58BINR174.13M · vs all stocks (USD)
Revenue per Share (TTM)
65.96INRUpdated Jul 20, 2026Quarterly Revenue Growth
15.00%Gross Profit (TTM)
7.82BINR82.17M · vs all stocks (USD)
EBITDA (TTM)
3.36BINR35.27M · vs all stocks (USD)
Net Income (TTM)
418.08MINR4.39M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
464.80%Operating Cash Flow (TTM)
1.04BINR10.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-14.90MINR-156.47K · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
658.88MINRFY2025 · Mar 31, 2025Revenue
15.47BINRFY2025 · Mar 31, 2025Cost of Goods Sold
8.64BINRFY2025 · Mar 31, 2025Gross Profit
6.83BINRFY2025 · Mar 31, 2025Operating Income
1.19BINR12.50M · vs all stocks (USD)
Pre-tax Income
443.06MINRFY2025 · Mar 31, 2025Income Tax Expense
120.47MINRFY2025 · Mar 31, 2025Net Income
322.59MINRFY2025 · Mar 31, 2025EBIT
1.00BINRFY2025 · Mar 31, 2025EBITDA (Income Statement)
1.63BINRFY2025 · Mar 31, 2025Selling, General & Administrative
893.95MINRFY2025 · Mar 31, 2025Other Operating Expenses
1.20BINRFY2025 · Mar 31, 2025Non-operating Interest Income
27.24MINRFY2025 · Mar 31, 2025Non-operating Interest Expense
559.56MINRFY2025 · Mar 31, 2025EPS (Basic)
0.8800INRFY2025 · Mar 31, 2025EPS (Diluted)
0.8500INRFY2025 · Mar 31, 2025Basic Shares Outstanding
249.38MSharesFY2025 · Mar 31, 2025Diluted Shares Outstanding
249.38MSharesFY2025 · Mar 31, 2025Minority Interests (P&L)
-103.81MINRFY2025 · Mar 31, 2025Preferred Stock Dividends
0.00INRFY2025 · Mar 31, 2025Operating Cash Flow
360.47MINRFY2025 · Mar 31, 2025Free Cash Flow
66.60MINRFY2025 · Mar 31, 2025Cash & Cash Equivalents (End of Period)
626.60MINRFY2025 · Mar 31, 2025Starting Profit (CF Statement)
443.06MINRFY2025 · Mar 31, 2025Stock-based Compensation
324.10MINRFY2025 · Mar 31, 2025Other Non-cash Items
541.41MINRFY2025 · Mar 31, 2025Change in Accounts Receivable (CF)
-479.40MINRFY2025 · Mar 31, 2025Change in Other Assets/Liabilities
-468.70MINRFY2025 · Mar 31, 2025Capital Expenditures
-293.87MINRFY2025 · Mar 31, 2025Other Investing Activity
-20.00KINRFY2025 · Mar 31, 2025Net Investing Cash Flow
-293.89MINRFY2025 · Mar 31, 2025Long-term Debt Issuance
2.68BINRFY2025 · Mar 31, 2025Long-term Debt Payments
-1.88BINRFY2025 · Mar 31, 2025Net Short-term Debt Issuance
-828.90MINRFY2025 · Mar 31, 2025Net Financing Cash Flow
48.38MINRFY2025 · Mar 31, 2025Shares Outstanding
435.72MSharesUpdated Jul 20, 2026Float Shares
96.00MSharesUpdated Jul 20, 2026% Held by Insiders
68.03%vs all stocks
% Held by Institutions
7.40%vs all stocks
Total Cash (MRQ)
709.00MINR7.45M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.84INRUpdated Jul 20, 2026Total Debt (MRQ)
4.90BINR51.50M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5531xCurrent Ratio (MRQ)
1.91xBook Value per Share (MRQ)
32.38INRUpdated Jul 20, 2026Total Assets
16.02BINR168.25M · vs all stocks (USD)
Total Current Assets
8.74BINRFY2025 · Mar 31, 2025Total Liabilities
8.32BINRFY2025 · Mar 31, 2025Total Non-current Assets
7.28BINRFY2025 · Mar 31, 2025Total Non-current Liabilities
3.27BINRFY2025 · Mar 31, 2025Total Current Liabilities
5.05BINRFY2025 · Mar 31, 2025Cash
611.71MINRFY2025 · Mar 31, 2025Cash Equivalents
14.89MINRFY2025 · Mar 31, 2025Cash & Cash Equivalents
626.60MINRFY2025 · Mar 31, 2025Other Short-term Investments
5.44MINRFY2025 · Mar 31, 2025Accounts Receivable
3.63BINRFY2025 · Mar 31, 2025Inventory
3.85BINRFY2025 · Mar 31, 2025Accounts Payable
2.57BINRFY2025 · Mar 31, 2025Short-term Debt
1.81BINRFY2025 · Mar 31, 2025Other Current Liabilities
214.50MINRFY2025 · Mar 31, 2025Long-term Debt
3.00BINRFY2025 · Mar 31, 2025Common Stock (Book)
500.60MINRFY2025 · Mar 31, 2025Retained Earnings
1.25BINRFY2025 · Mar 31, 2025Total Shareholders' Equity
7.70BINR80.91M · vs all stocks (USD)
Treasury Stock
24.72MINRFY2025 · Mar 31, 202552-Week Low
166.00INRUpdated Jul 20, 202652-Week High
298.00INRUpdated Jul 20, 202652-Week Change
43.13%vs all stocks
Beta
0.9640xvs all stocks
50-Day MA
208.71INRUpdated Jul 20, 2026200-Day MA
193.44INRUpdated Jul 20, 2026Avg 10-Day Volume
762.00KSharesUpdated Jul 20, 2026Avg 30-Day Volume
791.57KSharesUpdated Jul 20, 2026Diluted EPS (TTM)
1.63INRUpdated Jul 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.54Profit Margin: 0.03
Financial Health
Altman Z-Score 10.02: safe zoneNotable
Altman Z-Score: 10.02
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.23B, above the global median of $1.15BNotable
Market cap (USD): 1,232,421,926.565Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Viyash Scientific Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Carsgen Therapeutics Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MannKind Corporation
Tier 1ProductionApproval-Gated PipelineRule
Artivion Inc.
Tier 1ProductionApproval-Gated PipelineRule